{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:24:06Z","timestamp":1784118246731,"version":"3.55.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["224029\/Z\/21\/Z"],"award-info":[{"award-number":["224029\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Imperial NIHR Biomedical Research Centre"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Fluroquinolone prophylaxis during haematopoietic cell transplantation (HCT) remains contentious. We aimed to determine its effectiveness and association with exposure to treatment antimicrobials and antimicrobial resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All admission episodes for HCT (N\u200a=\u200a400\u200a, 372 unique patients) in a tertiary centre between January 2020 and December 2022 were studied. Allogeneic HCT (allo-HCT) recipients received prophylaxis with ciprofloxacin during chemotherapy-induced neutropenia, while autologous HCT (auto-HCT) recipients did not.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Allo-HCT was performed for 43.3% (173\/400) of patients, auto-HCT for 56.7% (227\/400). Allo-HCT was associated with an average of 1.01 fewer infection episodes per 100 admission days (95% CI 0.62\u20131.40, P\u200a&amp;lt;\u200a0.001) compared with auto-HCT. In allo-HCT, the total exposure to all antimicrobials was higher [+24.8 days of therapy (DOT)\/100 admission days, P\u200a&amp;lt;\u200a0.001], as was exposure to ciprofloxacin (+40.5 DOT\/100 admission days, P\u200a&amp;lt;\u200a0.001). By contrast, exposure to meropenem (\u22124.5 DOT\/100 admission days, P\u200a=\u200a0.02), piperacillin\/tazobactam (\u22125.2 DOT\/100 admission days, P\u200a&amp;lt;\u200a0.001), aminoglycosides (\u22124.5 DOT\/100 admission days, P\u200a&amp;lt;\u200a0.001) and glycopeptides (\u22126.4 DOT\/100 admission days, P\u200a&amp;lt;\u200a0.001) was reduced. Enterobacteriaceae isolated during allo-HCT were more resistant to ciprofloxacin (65.5%, 19\/29 versus 6.1%, 2\/33, P\u200a&amp;lt;\u200a0001), ceftriaxone (65.5%, 19\/29 versus 9.1%, 3\/33, P\u200a&amp;lt;\u200a0.001), other antimicrobial classes. Vancomycin-resistant enterococci were more common in allo-HCT recipients (11%, 19\/173 versus 0.9%, 2\/227, P\u200a&amp;lt;\u200a0.001). Inpatient mortality during allo- and auto-HCT was 9.8% (17\/173) and 0.4% (1\/227). respectively (P\u200a&amp;lt;\u200a0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ciprofloxacin prophylaxis in allo-HCT was associated with fewer infection episodes and reduced exposure to treatment antimicrobials. Mortality in auto-HCT remained low. A significant burden of antimicrobial resistance was detected in allo-HCT recipients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlae010","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T19:16:23Z","timestamp":1706814983000},"source":"Crossref","is-referenced-by-count":4,"title":["The effect of ciprofloxacin prophylaxis during haematopoietic cell transplantation on infection episodes, exposure to treatment antimicrobials and antimicrobial resistance: a single-centre retrospective cohort study"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-4835","authenticated-orcid":false,"given":"Ioannis","family":"Baltas","sequence":"first","affiliation":[{"name":"Department of Infection, Immunity and Inflammation, Institute of Child Health, University College London , London , UK"},{"name":"Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kavallieros","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giannis","family":"Konstantinou","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Koutoumanou","sequence":"additional","affiliation":[{"name":"Population, Policy & Practice Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malick M","family":"Gibani","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Faculty of Medicine, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gilchrist","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Faculty of Medicine, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1839-870X","authenticated-orcid":false,"given":"Frances","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Faculty of Medicine, Imperial College London , London , UK"},{"name":"Department of Infectious Disease, Imperial College NHS Healthcare Trust, St Mary's Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Pavlu","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust , London , UK"},{"name":"Faculty of Medicine, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2024022909291646900_dlae010-B1","doi-asserted-by":"crossref","first-page":"ofx050","DOI":"10.1093\/ofid\/ofx050","article-title":"Infections in hematopoietic cell transplant recipients: results from the organ transplant infection project, a multicenter, prospective, cohort study","volume":"4","author":"Schuster","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2024022909291646900_dlae010-B2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.idc.2010.01.010","article-title":"Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology","volume":"24","author":"Wingard","year":"2010","journal-title":"Infect Dis Clin"},{"key":"2024022909291646900_dlae010-B3","first-page":"CD004386","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2024022909291646900_dlae010-B4","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/cid\/cix646","article-title":"Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the infectious diseases working party of the European Bone Marrow Transplantation Group","volume":"65","author":"Averbuch","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024022909291646900_dlae010-B5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/tid.12298","article-title":"Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period","volume":"16","author":"Macesic","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"2024022909291646900_dlae010-B6","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"2024022909291646900_dlae010-B7","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cmi.2022.08.009","article-title":"The WHO essential medicines list AWaRe book: from a list to a quality improvement system","volume":"28","author":"Sharland","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024022909291646900_dlae010-B8","author":"Carreras"},{"key":"2024022909291646900_dlae010-B9","doi-asserted-by":"crossref","first-page":"m3339","DOI":"10.1136\/bmj.m3339","article-title":"Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score","volume":"370","author":"Knight","year":"2020","journal-title":"BMJ"},{"key":"2024022909291646900_dlae010-B10","author":"Gov.uk"},{"key":"2024022909291646900_dlae010-B11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4143\/crt.2014.034","article-title":"Clinical significance of non-neutropenic fever in the management of diffuse large B-cell lymphoma patients treated with rituximab-CHOP: comparison with febrile neutropenia and risk factor analysis","volume":"47","author":"Park","year":"2015","journal-title":"Cancer Res Treat"},{"key":"2024022909291646900_dlae010-B12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care\u2013associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"2024022909291646900_dlae010-B13","first-page":"1","article-title":"Bloodstream infection event (central line-associated bloodstream infection and non-central line-associated bloodstream infection)","author":"Centers for Disease Control Prevention","year":"2017","journal-title":"Device-Associated Module BSI"},{"key":"2024022909291646900_dlae010-B14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024022909291646900_dlae010-B15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cmi.2018.03.030","article-title":"Contaminants in blood cultures: importance, implications, interpretation and prevention","volume":"24","author":"Darg\u00e8re","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2024022909291646900_dlae010-B16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1086\/511640","article-title":"Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy","volume":"44","author":"Polk","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024022909291646900_dlae010-B17","volume-title":"Regression Diagnostics: Identifying Influential Data and Sources of Collinearity","author":"Belsley","year":"2005"},{"key":"2024022909291646900_dlae010-B18","first-page":"e1","article-title":"Safety and efficacy of prophylactic levofloxacin in pediatric and adult hematopoietic stem cell transplantation patients","volume":"28","author":"Gardner","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2024022909291646900_dlae010-B19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial","volume":"320","author":"Alexander","year":"2018","journal-title":"JAMA"},{"key":"2024022909291646900_dlae010-B20","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/cid\/cix644","article-title":"Levofloxacin prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia","volume":"65","author":"Wolf","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024022909291646900_dlae010-B21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/23744235.2016.1143963","article-title":"Ciprofloxacin prophylaxis delays initiation of broad-spectrum antibiotic therapy and reduces the overall use of antimicrobial agents during induction therapy for acute leukaemia: a single-centre study","volume":"48","author":"Hallb\u00f6\u00f6k","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"2024022909291646900_dlae010-B22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007890-199103000-00017","article-title":"Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation","volume":"51","author":"Lew","year":"1991","journal-title":"Transplantation"},{"key":"2024022909291646900_dlae010-B23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"key":"2024022909291646900_dlae010-B24","author":"Medicines and Healthcare Products Regulatory Agency"},{"key":"2024022909291646900_dlae010-B25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1473-3099(22)00014-7","article-title":"Antimicrobial use and resistance in England, 2020\u201321","volume":"22","author":"Venkatesan","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024022909291646900_dlae010-B26","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/cid\/ciz031","article-title":"Bloodstream infection due to vancomycin-resistant Enterococcus is associated with increased mortality after hematopoietic cell transplantation for acute leukemia and myelodysplastic syndrome: a multicenter, retrospective cohort study","volume":"69","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024022909291646900_dlae010-B27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1469-0691.2007.01840.x","article-title":"Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci","volume":"14","author":"Sakka","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2024022909291646900_dlae010-B28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/ajh.21855","article-title":"Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial","volume":"85","author":"Eleutherakis-Papaiakovou","year":"2010","journal-title":"Am J Hematol"},{"key":"2024022909291646900_dlae010-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-13-356","article-title":"Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance","volume":"13","author":"Garnica","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2024022909291646900_dlae010-B30","first-page":"295","article-title":"Levofloxacin prophylaxis in neutropenic patients","volume":"76","author":"Carena","year":"2016","journal-title":"Medicina (B Aires)"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/1\/dlae010\/56756066\/dlae010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/1\/dlae010\/56756066\/dlae010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:31:40Z","timestamp":1709199100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlae010\/7596053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlae010","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,12,28]]},"article-number":"dlae010"}}